MX2012007416A - Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. - Google Patents
Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.Info
- Publication number
- MX2012007416A MX2012007416A MX2012007416A MX2012007416A MX2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A
- Authority
- MX
- Mexico
- Prior art keywords
- angiogenesis
- compositions
- treatment
- methods
- eye diseases
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 3
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 3
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 abstract 2
- 108010049985 rhodostomin Proteins 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere generalmente a composiciones y métodos de tratamiento y/o prevención de enfermedades oculares relacionadas con la angiogénesis que emplean dosis bajas de variantes de rodostomina y, en particular, dosis bajas de una proteína de fusión que comprende una variante de rodostomina, en la cual la variante de rodostomina está conjugada con una variante de albúmina sérica humana (HSA) en donde el residuo cisteína en la posición 34 de la secuencia de aminoácidos de la HSA ha sido reemplazado con serina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28962409P | 2009-12-23 | 2009-12-23 | |
| PCT/US2010/061738 WO2011079175A1 (en) | 2009-12-23 | 2010-12-22 | Compositions and methods for the treatment of angiogenesis-related eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007416A true MX2012007416A (es) | 2012-07-23 |
Family
ID=44151942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007416A MX2012007416A (es) | 2009-12-23 | 2010-12-22 | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9044436B2 (es) |
| EP (1) | EP2515926A4 (es) |
| JP (1) | JP5739908B2 (es) |
| KR (1) | KR20120130752A (es) |
| CN (1) | CN102883738A (es) |
| AR (1) | AR079706A1 (es) |
| AU (1) | AU2010336475A1 (es) |
| BR (1) | BR112012015188A8 (es) |
| CA (1) | CA2782796A1 (es) |
| MX (1) | MX2012007416A (es) |
| NZ (1) | NZ600544A (es) |
| RU (1) | RU2012131251A (es) |
| TW (1) | TWI581801B (es) |
| WO (1) | WO2011079175A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2630253T3 (es) | 2009-02-11 | 2017-08-18 | Albumedix A/S | Variantes de albúmina y conjugados |
| TWI557224B (zh) * | 2009-07-20 | 2016-11-11 | 國立成功大學 | 具αｖβ３整合蛋白選擇性且與人類血清白蛋白（ＨＳＡ）變體結合之多肽及其於醫藥上之用途 |
| US8748380B2 (en) | 2009-10-30 | 2014-06-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| ES2664328T3 (es) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Variantes de albúmina |
| BR112015010318A2 (pt) | 2012-11-08 | 2017-08-22 | Albumedix As | Variantes de albumina |
| WO2015147616A1 (ko) * | 2014-03-28 | 2015-10-01 | 연세대학교 산학협력단 | Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물 |
| WO2016029131A1 (en) * | 2014-08-22 | 2016-02-25 | National Cheng Kung University | Disintegrin variants and pharmaceutical uses thereof |
| WO2016108669A1 (ko) * | 2014-12-31 | 2016-07-07 | 주식회사 휴온스 | Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물 |
| ES2797901T3 (es) * | 2015-06-28 | 2020-12-04 | Allgenesis Biotherapeutics Inc | Proteínas de fusión para la inhibición de angiogénesis |
| US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
| US12304037B2 (en) | 2021-11-03 | 2025-05-20 | Aob Products Company | Torque driver |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| KR20250021281A (ko) | 2023-08-04 | 2025-02-12 | 주식회사 넥스세라 | 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6710030B1 (en) * | 1993-10-22 | 2004-03-23 | University Of Southern California | Contortrostain (CN) and methods for its use in preventing metastasis and other conditions |
| US5659018A (en) * | 1995-08-01 | 1997-08-19 | Genetics Institute, Inc. | Mocarhagin, a cobra venom protease, and therapeutic uses thereof |
| AU2002339862A1 (en) * | 2001-09-04 | 2003-05-26 | Aventis Pharmaceuticals Inc. | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis |
| WO2003104243A1 (en) | 2002-06-07 | 2003-12-18 | Wisconsin Alumni Research Foundation | Chemical synthesis of reagents for peptide coupling |
| EP1881849A2 (en) * | 2005-04-29 | 2008-01-30 | Research Development Foundation | Vascular targeting of ocular neovascularization |
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| TWI557224B (zh) * | 2009-07-20 | 2016-11-11 | 國立成功大學 | 具αｖβ３整合蛋白選擇性且與人類血清白蛋白（ＨＳＡ）變體結合之多肽及其於醫藥上之用途 |
-
2010
- 2010-12-22 US US12/975,630 patent/US9044436B2/en not_active Expired - Fee Related
- 2010-12-22 CN CN2010800594090A patent/CN102883738A/zh active Pending
- 2010-12-22 BR BR112012015188A patent/BR112012015188A8/pt not_active IP Right Cessation
- 2010-12-22 RU RU2012131251/15A patent/RU2012131251A/ru not_active Application Discontinuation
- 2010-12-22 CA CA2782796A patent/CA2782796A1/en not_active Abandoned
- 2010-12-22 NZ NZ600544A patent/NZ600544A/en not_active IP Right Cessation
- 2010-12-22 AU AU2010336475A patent/AU2010336475A1/en not_active Abandoned
- 2010-12-22 AR ARP100104891A patent/AR079706A1/es unknown
- 2010-12-22 WO PCT/US2010/061738 patent/WO2011079175A1/en not_active Ceased
- 2010-12-22 MX MX2012007416A patent/MX2012007416A/es not_active Application Discontinuation
- 2010-12-22 KR KR1020127019529A patent/KR20120130752A/ko not_active Withdrawn
- 2010-12-22 EP EP20100840104 patent/EP2515926A4/en not_active Withdrawn
- 2010-12-22 JP JP2012546185A patent/JP5739908B2/ja not_active Expired - Fee Related
- 2010-12-23 TW TW099145616A patent/TWI581801B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110152192A1 (en) | 2011-06-23 |
| BR112012015188A8 (pt) | 2016-08-09 |
| JP5739908B2 (ja) | 2015-06-24 |
| KR20120130752A (ko) | 2012-12-03 |
| CA2782796A1 (en) | 2011-06-30 |
| TW201138801A (en) | 2011-11-16 |
| AR079706A1 (es) | 2012-02-15 |
| BR112012015188A2 (pt) | 2016-04-05 |
| US9044436B2 (en) | 2015-06-02 |
| EP2515926A4 (en) | 2013-10-09 |
| NZ600544A (en) | 2014-06-27 |
| CN102883738A (zh) | 2013-01-16 |
| EP2515926A1 (en) | 2012-10-31 |
| JP2013515739A (ja) | 2013-05-09 |
| WO2011079175A1 (en) | 2011-06-30 |
| TWI581801B (zh) | 2017-05-11 |
| AU2010336475A1 (en) | 2012-06-14 |
| RU2012131251A (ru) | 2014-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
| AR123908A2 (es) | Proteínas de fusión para tratar trastorno metabólicos | |
| UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| IN2014CN04498A (es) | ||
| WO2009011544A3 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
| SG196821A1 (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| MY188696A (en) | Cysteine protease | |
| BR112012017348A2 (pt) | "análogo de peptídeo de oxintomodulina" | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| MX2010004571A (es) | Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos. | |
| WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
| EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
| NO20082510L (no) | En fremgangsmate for konsentrasjon av et polypeptid | |
| MX2011012677A (es) | Conjugados de albumina-peptido amiloide y usos de los mismos. | |
| ATE506957T1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| ECSP10010516A (es) | Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
| WO2007145589A8 (en) | Peptides that are capable of binding to amyloid-beta peptide. | |
| WO2011051916A3 (en) | Stabilized protein formulations and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: NATIONAL CHENG KUNG UNIVERSITY.* |
|
| FA | Abandonment or withdrawal |